Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs

Journal of Agricultural and Food Chemistry

Volumn 56, Issue 22, 2008, Pages 10582-10593

  Balogh, Lajos ^a   Polyak, Andras ^a   Mathe, Domokos ^a   Kiraly, Reka ^a   Thuroczy, Juliana ^a   Terez, Marian ^a   Janoki, Gyozo ^a   Ting, Yao ^b   Bucci, Luke R ^c   Schauss, Alexander G ^d  

^a National Research Institute for Radiobiology and Radiohygiene Budapest   (Hungary)

^b FenChem Biotek Ltd   (China)

^c Schiff Nutrition International   (United States)

^d Life Sciences Division   (United States)

Author keywords

99mTechnetium; Dietary supplements; Hyaluronan; Joint tissues; Oral absorption; Scintigraphy

Indexed keywords

HYALURONIC ACID; TECHNETIUM;

ABSORPTION; ANIMAL; ARTICLE; CHEMISTRY; DOG; FECES; ISOTOPE LABELING; MOLECULAR WEIGHT; RAT; TISSUE DISTRIBUTION; URINE; WISTAR RAT;

ABSORPTION; ANIMALS; DOGS; FECES; HYALURONIC ACID; ISOTOPE LABELING; MOLECULAR WEIGHT; RATS; RATS, WISTAR; TECHNETIUM; TISSUE DISTRIBUTION;

CANIS FAMILIARIS; RATTUS; RATTUS NORVEGICUS;

EID: 57849165565     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf8017029     Document Type: Article

References (58)

1. Bucci, L. R.; Turpin, A. A. Will the real hyaluronan please stand up? J. Appl. Nutr. 2004, 54, 10-33.
2. Laurent, T. C.; Fraser, J. R. E. Hyaluronan. FASEB J. 1992, 6, 2397-2404.
3. Kogan, G.; Sokes, L.; Stern, R.; Gemeiner, P. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol. Lett. 2007, 29, 17-25.
4. Dietary Supplement Health and Education Act of 1994 (DSHEA), Public Law 103-417. Fed. Regist. 1994, 59, 4325-4329.
5. Samson, D. J.; Grant, M. D.; Ratko, T. A.; Bonnell, C. J.; Ziegler, K. M.; Aronson, N. Treatment of primary and secondary osteoarthritis of the knee. Evidence Report/Technology Assessment No. 157 (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence based Practice Center under Contract No. 290-02-0026). AHRQ Publication No. 07-E012. Rockville, MD: Agency for Healthcare Research and Quality. September 2007.
6. Campbell, J.; Bellamy, N.; Gee, T. Differences between systematic reviews/meta-analyses of hyaluronic acid/hyaluronan/Hylan in osteoarthritis of the knee. Osteoarthritis Cartilage 2007, 15, 1424-1436.
7. Dilworth, J. R.; Parrott, S. J. The biomedical chemistry of technetium and rhenium. Chem. Soc. Rev. 1998, 27, 43-55.
8. Balogh, L.; ocs, G.; Thuroczy, J.; Nemeth, T.; Lang, J.; Bodo, K.; Janoki, G. A. Veterinary nuclear medicine. Scintigraphical examinations - a review. Acta Vet. Brno 1999, 68, 231-239.
9. 99mtechnetium labeled hyaluronan after single oral doses in rats and beagle dogs. Fed. Am. Soc. Exp. Biol. J. 2004, 18, A150-A151[abstract 129.4]
10. Balogh, L.; Kerekes, A.; Bodó, K.; Körösi, L.; Jánoki, G. A. [Evaluation of a complex trace element composition and bi-outilization using isotope technics and total body measurement]. Orv. Hetil. 1998, 139, 1297-1302.
11. 35S-sodium chondroitin polysulfate in rats. Oyo Yakuri 1972, (2), 405-413.
12. Morrison, L. M.; Schjeide, O. A.; Murata, K. Absorption, distribution, metabolism and excretion of acid mucopolysaccharides administered to animals and patients. In Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans); Morrison, L. M., Schjeide, O. A. Eds.; Charles C. Thomas: Springfield, 1974; pp 109-127.
13. Konador, A.; Kawiak, J. Distribution of radioactivity in the mouse organism after administration of 35S-chondroitin sulphate. Folia Biol. (Krakow) 1976, 24, 177-190.
14. Thilo, G. Etude de 35 cas d'arthrose traités par l'acide chondroïtine sulfurique. [A study of 35 cases of arthrosis treated with Chondroitin Sulfuric Acid]. Schweiz Rundsch. Med/Prax. 1977, 66, 1696-1699.
15. Pescador, R.; Diamantini, G.; Mantovani, M.; Malandrino, S.; Riva, A.; Casu, B.; Oreste, P. Absorption by the rat intestinal tract of fluorescein-labelled pig duodenal glycosaminoglycans. Arzneim. Forsch. 1980, 30, 1893-1896.
16. Pescador, R.; Madonna, M. Pharmacokinetics of fluorescein-labelled glycosaminoglycans and of their lipoprotein lipase-inducing activity in the rat. Arzneim. Forsch. 1982, 32, 819-824.
17. Clevidence, B. A.; Failla, M. L.; Vercellotti, J. R.; Pescador, R. Pharmacokinetics of catalytically tritiated glycosaminoglycans in the rat. Arzneim. Forsch. 1983, 33, 228-230.
18. Gross, D. Orale chondroitin-Sulfatmedikation zur behandlung von arthrosen. [Oral chondroitin sulfate medication for the treatment of osteoarthritis]. Therapiewoche 1983, 33, 4238-4244.
19. Ronca, G.; Ronca-Testoni, S.; Lualdi, P. Pharmacocinetique du chondroitin sulfate-3H après administration orale chez l'animal [abstract]. Z. Rheumatol. 1988, 47, 325-326.
20. Dawes, J.; Hodson, B. A.; Pepper, D. S. The absorption, clearance and metabolic fate of dermatan sulphate administered to man-studies using a radioiodinated derivative. Thromb. Haemostasis 1989, 62, 945-949.
21. Dawes, J.; Hodson, B. A.; MacGregor, I. R.; Pepper, D. S.; Prowse, C. V. Pharmacokinetic and biological activities of dermatan sulfate (Mediolanum MF701) in healthy human volunteers. Ann. N.Y. Acad. Sci. 1989, 556, 292-303.
22. Palmieri, L.; Conte, A.; Giovannini, L.; Lualdi, P.; Ronca, G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneim. Forsch. 1990, 40, 319-323.
23. Conte, A.; Palmieri, L.; Segnini, D.; Ronca, G. Metabolic fate of partially depolymerized chondroitin sulfate administered to the rat. Drugs Exp. Clin. Res. 1991, 17, 27-33.
24. Conte, A.; de Bernardi, M.; Palmieri, L.; Lualdi, P.; Mautone, G.; Ronca, G. Metabolic Fate of Exogenous Chondroitin Sulfate in Man. Arzneim. Forsch. 1991, 41, 768-772.
25. Dawes, J.; McLaren, M.; Forbes, C.; Belch, J. J.; Lane, D. A.; Bray, B.; McEwen, J.; Houin, G.; Gianese, F. The pharmacokinetics of dermatan sulphate MF701 in healthy human volunteers. Br. J. Clin. Pharmacol. 1991, 32, 361-366.
26. Ronca, G.; Conte, A. Metabolic fate of partially depolymerized shark chondroitin sulfate in man. Int. J. Clin. Pharmacol. Res. 1993, 13, 27-34.
27. Silvestro, L.; Lanzarotti, E.; Marchi, E.; Gori, M.; Pescador, R.; Ferro, L.; Nilani, M. R.; Da Col, R.; Coppini, A. Human pharmacokinetics of glycosaminoglycans using deuterium-labeled and unlabeled substances: evidence for oral absorption. Semin. Thromb. Hemostasis 1994, 20, 281-292.
28. Conte, A.; Volpi, N.; Palmieri, L.; Bahous, I.; Ronca, G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneim. Forsch. 1995, 45, 918-925.
29. Volpi, N. Physico-chemical properties and the structure of dermatan sulfate fractions purified from plasma after oral administration in healthy human volunteers. Thromb. Haemostasis 1996, 75, 491-496.
30. Ronca, F.; Palmieri, L.; Panicucci, P.; Ronca, G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998, 6, 14-21.
31. Imanari, T.; Washio, Y.; Huang, Y.; Toyoda, H.; Suzuki, A.; Toida, T. Oral absorption and clearance of partially depolymerized fucosyl chondroitin sulfate from sea cucumber. Thromb. Res. 1999, 93, 129-135.
32. Eddington, N. D.; Du, J.; White, N. Evidence of the Oral Absorption of Chondroitin Sulfate as Determined by Total Disaccharide Content After Oral and Intravenous Administration to Horses. A.A.E.P. Proc. 2001, 47, 326-328.
33. Adebowale, A.; Du, L.; Liang, Z.; Leslie, J. L.; Eddington, N. D. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm. Drug Dispos. 2002, 23, 217-225.
34. Volpi, N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis Cartilage 2002, 10, 768-777.
35. Volpi, N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis Cartilage 2003, 11, 433-441.
36. Barthe, L.; Woodley, J.; Lavit, M.; Przybylski, C.; Philibert, C.; Houin, G. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneim. Forsch. 2004, 54, 286-292.
37. Du, J.; White, N.; Eddington, N. D. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm. Drug Dispos. 2004, 25, 109-116.
38. Lamari, F. N.; Theocharis, A. D.; Asimakopoulou, A. P.; Malakavi, C. J.; Karamanos, N. K. Metabolism and biochemical/physiological roles of chondroitin sulfates: analysis of endogenous and supplemental chondroitin sulfates in blood circulation. Biomed. Chromatogr. 2006, 20, 539-550.
39. Hiebert, L. M. Oral heparins. Clin. Lab. 2002, 48, 111-116.
40. Pineo, G; Hull, R; Marder, V. Oral delivery of heparin: SNAC and related formulations. Best Pract. Res., Clin. Haematol. 2004, 17, 153-160.
41. Arbit, E.; Goldberg, M.; Gomez-Orellana, I.; Majuru, S. Oral heparin: status review. Thromb. J. 2006, 4, 6.
42. Konador, A.; Kawiak, J. Changes in chondroitin sulfate concentration in rabbit blood plasma depending on the method of its administration. Arch. Immunol. Ther. Exp. 1977, 25, 895-903.
43. Andermann, G.; Dietz, M. The influence of the route of administration on the bioavailability of an endogenous macromolecule: chondroitin sulphate (CSA). Eur. J. Drug Metab. Pharmacokinet. 1982, 7, 11-16.
44. Baici, A.; Horler, D.; Moser, B.; Hofer, H. O.; Fehr, K.; Wagenhauser, F. J. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol. Int. 1992, 12, 81-88.
45. Jackson, C. G.; Plaas, A. H.; Barnhill, J. G.; Harris, C. L.; Clegg, D. O. The pharmacokinetics of oral glucosamine and chondroitin sulfate in humans [abstract 488 L13]. In American College of Rheumatology Annual Scientific Meeting: 13-17 November 2005; San Diego; American College of Rheumatology: Atlanta, GA, 2005; p 15.
46. Pierce, S. W. Efficacy of orally administered sodium hyaluronate gel in the racing thoroughbred. In Hyaluronan 2003 Proceedings. Chapter 6 Musculoskelatal System: Balazs, E. A., Hascall, V. C., Eds.; Matrix Biology Institute: Cleveland, OH, 2004; pp 1-4.
47. Stancikova, M.; Svik, K.; Istok, R.; Rovensky, J.; Velebny, V. The effects of hyaluronan on bone resorption and bone mineral density in a rat model of estrogen deficiency-induced osteopenia. Int. J. Tissue React. 2004, 26, 9-16.
48. Bergin, B. J.; Pierce, S. W.; Bramlage, L. R.; Stromberg, A. Oral hyaluronan gel reduces post operative tarsocrural effusion in the yearling Thoroughbred. Equine Vet. J. 2006, 38, 375-378.
49. Martinez-Puig, D.; Carmona, J. U.; Arguelles, D.; Deulofeu, R.; Ubia, A.; Prades, M. Oral hyaluronic acid administration improves osteochondrosis clinical symptoms and slightly increses intraarticular concentration of hyaluronic acid in a horse model: a pilot survey. Osteoarthritis Cartilage 2007, 15, C62-C63(abstract 96).
50. Kalman, D. S.; Heimer, M.; Valdeon, A.; Schwartz, H.; Sheldon, E. Effect of a natural extract of chickencombs with a high content of hyaluronic acid (Hyal-Joint®) on pain relief and quality of life in subjects with knee osteoarthritis: a pilot randomized double-blind placebo-controlled trial. Nutr. J. 2008, 7 (3), 1-9.
51. Bucci, L. R.; Sheldon, E.; Schwartz, H.; Pachon, J.; Kalman, D.; Mederos, M.; Pezzullo, J. C.; Beer, C. Comparison between glucosamine with chondroitin sulfate and glucosamine with chondroitin sulfate and hyaluronate for symptoms of knee osteoarthritis. Osteoarthritis Cartilage 2005, 13, S99.
52. Florence, A. T.; Jani, P. U. Oral uptake of microparticles across the gastrointestinal mucosa. In Drug Targeting and Delivery: Concepts in Dosage Form Design; Junginger, H. E., Ed.; Ellis Horwood: New York, NY, 1992; pp 113-128.
53. Thanos, C. G.; Yip, K. P.; Mathiowitz, E. Intestinal uptake of polymer microspheres in the rabbit studied with confocal microscopy. J. Bioact. Compat. Polym. 2004, 19, 247-266.
54. Knudson, C. B.; Knudson, W. Hyaluronan and CD44: modulators of chondrocyte metabolism. Clin. Orthop. Relat. Res. 2004(Suppl. 427), 152-162.
55. Jiang, D.; Liang, J.; Noble, P. W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 2007, 23, 435-461.
56. Liu, N. Metabolism of macromolecules in tissue. Lymphat. Res. Biol. 2003, 1 (1), 67-70.
57. Liu, N. Trafficking of hyaluronan in the interstitium and its possible implications. Lymphology 2004, 37 (1), 6-14.
58. Breborowicz, A.; Moberly, J. B.; Pawlaczyk, K.; Polubinska, A.; Kuzlan-Pawlaczyk, M.; Wieczorowska-Tobis, K.; Ogle, K.; Martos, L.; Oreopoulos, D. G. Effects of hyaluronan used as a supplement in peritoneal dialysis solutions. In Hyaluronan. Volume 2. Biomedical, Medical and Clinical Aspects; Kennedy, J. F., Phillips, G. O., Williams, P. A., Hascall, V. C., Eds.; Woodhead Publishing Unlimited: Cambridge, England, 2002; Vol. 2, pp 453-460.